The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation
Pharmaceuticals · 19.02.2025 · 18 (2) · 274
DOI: 10.3390/ph18020274 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.02.2025. Verfasst von Adel S Girgis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Centre, Egypt, College of Science and Mathematics and the Augusta University Provost’s office, Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University.
Abstract (Originalsprache)
The p53, often referred to as the “guardian of the genome”, is a well-established tumor-suppressor protein that plays a critical role in regulating the cell cycle, DNA repair, differentiation, and apoptosis, with its activity primarily modulated by the MDM2 protein (murine double minute 2, also known as HDM2 in humans). Disrupting the protein-protein interaction between p53 and MDM2 represents a promising therapeutic strategy for developing anticancer agents. Recent studies have shown that several spirooxindole-containing compounds exhibit significant antitumor properties, primarily by inhibiting the p53–MDM2 interaction. This review provides an overview of structure-based spirooxindoles that could have therapeutic potential. It highlights findings from the past decade concerning their antiproliferative properties and implications for interfering with the p53–MDM2 interaction. The discussion includes various analogs of spirooxindoles as promising candidates for optimizing leads in drug discovery programs aimed at developing novel and clinically effective agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt.
- State Key Laboratory of Drug Research and Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Rd, Shanghai 201203, China.
- Department of Chemistry and Biochemistry, Augusta University, Augusta, GA 30912, USA.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
- Department of Chemistry, Faculty of Science, Helwan University, Helwan 11795, Egypt.
- Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA 30912, USA.
ORCID-Profile: Adel S Girgis, Yujun Zhao, Angel Nkosi, Dalia R Aboshouk, Siva S Panda
Förderung
- National Research Centre, Egypt
- College of Science and Mathematics and the Augusta University Provost’s office
- Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University
Zitieren
APA
Girgis, A. S., Zhao, Y., Nkosi, A., Ismail, N. S. M., Bekheit, M. S., Aboshouk, D. R., Aziz, M. N., Youssef, M. A., & Panda, S. S. (2025). The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation. Pharmaceuticals, 18(2), 274. https://doi.org/10.3390/ph18020274
Vancouver
Girgis AS, Zhao Y, Nkosi A, Ismail NSM, Bekheit MS, Aboshouk DR, et al. The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation. Pharmaceuticals. 2025;18(2):274. doi:10.3390/ph18020274
BibTeX
@article{Girgis2025,
author = {Girgis, Adel S and Zhao, Yujun and Nkosi, Angel and Ismail, Nasser S M and Bekheit, Mohamed S and Aboshouk, Dalia R and Aziz, Marian N and Youssef, M Adel and Panda, Siva S},
title = {The Therapeutic Potential of Spirooxindoles in Cancer: A Focus on p53–MDM2 Modulation},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {2},
pages = {274},
doi = {10.3390/ph18020274}
}
EUVIMED